A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
EQUASENS operates in the Medical - Healthcare Information Services industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 234M | 234M | 239M | 225M | 228M | 197M |
| Net Income | 39M | 39M | 51M | 51M | 49M | 38M |
| EPS | $2.58 | $2.58 | $3.37 | $3.21 | $3.04 | $2.32 |
| Free Cash Flow | 51M | 51M | 63M | 60M | 56M | 54M |
| ROIC | 16.1% | 12.3% | 17.5% | 18.3% | 20.3% | 21.3% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.24 | 0.27 | 0.25 | 0.38 | 0.37 |
| Dividends/Share | $1.35 | $1.35 | $1.25 | $1.11 | $1.06 | $0.97 |
| Operating Income | 47M | 47M | 60M | 58M | 59M | 53M |
| Operating Margin | 20.2% | 20.2% | 25.1% | 25.8% | 26.0% | 26.9% |
| ROE | 15.7% | 16.0% | 22.9% | 25.5% | 26.5% | 23.5% |
| Shares Outstanding | 15M | 15M | 15M | 16M | 16M | 16M |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 177M | 197M | 228M | 225M | 239M | 234M | 234M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | 46M | 53M | 59M | 58M | 60M | 47M | 47M |
| Op. Margin | 25.8% | 26.9% | 26.0% | 25.8% | 25.1% | 20.2% | 20.2% |
| Net Income | 34M | 38M | 49M | 51M | 51M | 39M | 39M |
| Net Margin | 19.1% | 19.0% | 21.3% | 22.7% | 21.4% | 16.7% | 16.7% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||
| ROIC | 19.4% | 21.3% | 20.3% | 18.3% | 17.5% | 12.3% | 16.1% |
| ROE | 23.0% | 23.5% | 26.5% | 25.5% | 22.9% | 16.0% | 15.7% |
| ROA | 11.8% | 11.9% | 13.3% | 13.5% | 12.8% | 9.1% | 9.1% |
| Cash Flow | |||||||
| Op. Cash Flow | 46M | 54M | 56M | 60M | 63M | 51M | 51M |
| Free Cash Flow | 46M | 54M | 56M | 60M | 63M | 51M | 51M |
| Owner Earnings | 37M | 44M | 43M | 47M | 48M | 35M | 35M |
| CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Maint. CapEx | 8.3M | 10M | 13M | 13M | 14M | 16M | 16M |
| Growth CapEx | N/A | N/A | N/A | N/A | N/A | N/A | 0 |
| D&A | 8.3M | 10M | 13M | 13M | 14M | 16M | 16M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||
| Dividends Paid | 14M | 16M | 17M | 17M | 19M | 20M | 20M |
| Dividend Yield | 1.4% | 1.1% | 0.9% | 1.3% | 1.6% | 2.5% | 3.4% |
| Share Buybacks | 16M | 0 | 6.1M | 7.7M | 5.6M | 6.6M | 6.6M |
| Buyback Yield | 1.4% | 0.0% | 0.4% | 0.6% | 0.6% | 1.0% | 1.1% |
| Stock-Based Comp | N/A | N/A | N/A | 371K | 382K | 351K | 351K |
| Debt Repayment | 9.9M | 13M | 18M | 16M | 22M | 26M | 26M |
| Balance Sheet | |||||||
| Net Debt | 29M | 25M | 47M | 27M | 43M | 43M | -17M |
| Cash & Equiv. | 24M | 39M | 27M | 25M | 20M | 17M | 17M |
| Long-Term Debt | 53M | 63M | 75M | 51M | N/A | N/A | N/A |
| Debt/Equity | 0.36 | 0.37 | 0.38 | 0.25 | 0.27 | 0.24 | 0.00 |
| Interest Coverage | 81.2 | 80.8 | 85.3 | 81.3 | 82.5 | 39.8 | 39.8 |
| Equity | 148M | 171M | 195M | 207M | 238M | 250M | 250M |
| Total Assets | 289M | 340M | 389M | 369M | 428M | 430M | 430M |
| Total Liabilities | 141M | 169M | 194M | 162M | 190M | 180M | 180M |
| Intangibles | N/A | N/A | N/A | N/A | 44M | 50M | 50M |
| Retained Earnings | 108M | 126M | N/A | N/A | N/A | N/A | N/A |
| Working Capital | 28M | 34M | 33M | 41M | 26M | 23M | 23M |
| Current Assets | 109M | 127M | 144M | 144M | 144M | 132M | 132M |
| Current Liabilities | 81M | 93M | 111M | 103M | 117M | 110M | 110M |
| Per Share Data | |||||||
| EPS | 2.09 | 2.32 | 3.04 | 3.21 | 3.37 | 2.58 | 2.58 |
| Owner EPS | 2.31 | 2.74 | 2.70 | 2.95 | 3.19 | 2.33 | 2.33 |
| Book Value | 9.19 | 10.68 | 12.32 | 13.11 | 15.84 | 16.64 | 16.64 |
| Cash Flow/Share | 2.83 | 3.39 | 3.54 | 3.79 | 4.17 | 3.42 | 3.67 |
| Dividends/Share | 0.89 | 0.97 | 1.06 | 1.11 | 1.25 | 1.35 | 1.35 |
| Shares Out. | 16.1M | 16.0M | 15.8M | 15.8M | 15.0M | 15.0M | 15.0M |
| Valuation | |||||||
| P/E Ratio | 32.5 | 55.7 | 32.1 | 24.2 | 20.1 | 17.8 | 15.3 |
| P/FCF | 24.0 | 38.1 | 27.6 | 20.4 | 16.2 | 13.5 | 11.6 |
| EV/EBIT | 24.5 | 39.5 | 26.8 | 21.6 | 17.7 | 15.6 | 12.2 |
| Price/Book | 7.4 | 12.1 | 7.9 | 5.9 | 4.3 | 2.8 | 2.4 |
| Price/Sales | 6.2 | 10.5 | 6.8 | 5.4 | 4.3 | 3.0 | 2.5 |
| FCF Yield | 4.2% | 2.6% | 3.6% | 4.9% | 6.2% | 7.4% | 8.7% |
| Market Cap | 1.1B | 2.1B | 1.5B | 1.2B | 1.0B | 692M | 594M |
| Avg. Price | 63.70 | 85.73 | 114.77 | 82.47 | 79.94 | 55.01 | 39.50 |
| Year-End Price | 68.00 | 129.15 | 97.62 | 77.57 | 67.55 | 46.05 | 39.50 |
EQUASENS passes 4 of 9 quality checks, suggesting mixed fundamentals.
EQUASENS trades at 15.3x trailing earnings, compared to its 15-year median P/E of 28.1x, suggesting it is currently Cheap relative to its historical range. On a free-cash-flow basis, the stock trades at 11.6x vs a median of 22.2x. The company's 5-year average ROIC is 18.0%. Total shareholder yield (dividends + buybacks) is 4.5%. At current prices, the estimated annualized return to fair value is +4.4%.
EQUASENS (EQS-PA) has a current P/E ratio of 15.3, compared to its historical median P/E of 28.1. The stock is currently considered Cheap based on its historical valuation range.
EQUASENS (EQS-PA) has a 5-year average return on invested capital (ROIC) of 18.0%. This indicates strong capital allocation and a potential competitive advantage.
EQUASENS (EQS-PA) has a market capitalization of $594M. It is classified as a small-cap stock.
Yes, EQUASENS (EQS-PA) pays a dividend with a trailing twelve-month yield of 3.42%. The company also returns capital through share buybacks, with a buyback yield of 1.11%.
Based on historical P/E analysis, EQUASENS (EQS-PA) appears cheap. The current P/E of 15.3 is 46% below its historical median of 28.1. The estimated fair value CAGR (P/E method) is 5.9%.
EQUASENS (EQS-PA) operates in the Medical - Healthcare Information Services industry, within the Healthcare sector.
EQUASENS (EQS-PA) reported annual revenue of $234 million in its most recent fiscal year, based on SEC EDGAR filings.
EQUASENS (EQS-PA) has a net profit margin of 16.7%. This is a healthy margin.
EQUASENS (EQS-PA) generated $51 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
EQUASENS (EQS-PA) has a debt-to-equity ratio of 0.24. This indicates a conservatively financed balance sheet.
EQUASENS (EQS-PA) reported earnings per share (EPS) of $2.58 in its most recent fiscal year.
EQUASENS (EQS-PA) has a return on equity (ROE) of 16.0%. This indicates the company generates strong returns for shareholders.
The Ledger Terminal provides 6 years of financial data for EQUASENS (EQS-PA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
EQUASENS (EQS-PA) has a book value per share of $16.64, based on its most recent annual SEC filing.